First Diagnostic Agent Approved to Image Tau Pathology in Patients Being Evaluated for Alzheimer Disease
Tauvid is indicated for use with positron emission tomography (PET) imaging of the brain.
Diagnostic Agents
Interim Data on Abbott ID NOW COVID-19 Rapid Test Performance Announced
An ongoing clinical study of the Abbott ID NOW™ COVID-19 rapid test shows strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments.
FDA Authorizes At-Home Sample Collection Kit for Use With Multiple COVID-19 Diagnostics
The kit will be available only by prescription to individuals who have been screened using an online questionnaire that is reviewed by a healthcare provider.
FDA: False Negatives Possible With Abbott’s Rapid COVID-19 Test
According to the Food and Drug Administration, the Abbott ID Now™ point-of-care test to diagnose coronavirus disease 2019 (COVID-19) may return false negative results based on early data.
LabCorp Expands Access to COVID-19 At-Home Collection Test Kit
LabCorp has expanded access to its at-home collection test kit to individuals nationwide who have symptoms consistent with coronavirus disease 2019 (COVID-19) and those without symptoms who may have been exposed to the virus.
ACR Issues Statement on Return of Routine Radiology Services
Comprehensive strategy for safe resumption should consider local COVID-19 statistics, PPE availability.
COVID-19 Diagnostics Update: First Antigen Test, New At-Home Saliva Collection Kit
The FDA has issued Emergency Use Authorization (EUA) to 2 new coronavirus disease 2019 (COVID-19) diagnostics.
FDA Goes After Unproven COVID-19 Antibody Tests
Companies selling tests will be required to submit data proving accuracy within next 10 days.
NIH Launches $500 Million Contest to Produce Best COVID-19 Test
Goal is to make millions of tests available to Americans each week by end of summer.
MPR Weekly Dose Podcast Episode 31
Episode 31 runs through the top COVID-19 stories including a steep rise in poison control calls; The authorization of an at-home testing kit; The hydroxychloroquine trial that’s beginning soon; The trial evaluating ruxolitinib for COVID-19 associated cytokine storms; And the lab failures which led to ineffective COVID-19 tests being sent from the CDC to nearly all…
